瑞波西利治疗在激素受体阳性乳腺癌患者中显示出有利的免疫调节效应——RIBECCA试验结果
RIBECCA试验预设探索性亚分析显示,转移性激素受体阳性乳腺癌患者接受瑞波西利治疗12周后,外周血基因表达分析显示适应性免疫激活相关特征上调、免疫抑制性细胞因子信号下降,调节性T细胞频率降低且与治疗反应相关,CD4+初始T细胞诱导增加,而效应和记忆T细胞群及T细胞受体多样性基本不变。作者认为这些效应提示对既有免疫应答的激活而非从头诱导。
要点
- 瑞波西利治疗12周后外周血适应性免疫激活特征上调、免疫抑制性细胞因子信号下降。
- 外周调节性T细胞频率降低,且该降低与治疗反应相关。
- CD4+初始T细胞诱导增加,效应和记忆T细胞群及T细胞受体多样性基本不变。
核心结论
- 瑞波西利治疗对激素受体阳性乳腺癌患者的外周固有和适应性免疫应答具有显著影响。
- 数据提示这些效应导致对既有免疫应答的激活而非从头诱导,为CDK4/6抑制剂与免疫治疗联合策略提供了有力依据。
研究设计与样本
- RIBECCA试验(NCT03096847)的预设探索性亚分析。
- 研究对象为转移性激素受体阳性乳腺癌患者,在治疗开始前和瑞波西利治疗12周后采集外周血单个核细胞。
- 方法包括免疫细胞谱分析、免疫相关特征基因表达分析和深度T细胞受体谱分析。
主要发现
- 基因表达分析显示瑞波西利治疗期间适应性免疫系统激活相关特征上调,免疫抑制性细胞因子信号下降。
- 外周免疫细胞亚群分析显示调节性T细胞频率降低,且与治疗反应相关。
- 可见CD4+初始T细胞诱导,而效应和记忆T细胞群基本不变。
- T细胞受体库多样性治疗期间基本不变,但个别患者可观察到克隆性增加。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Inhibitors of the cyclin-dependent kinases 4 and 6 (CDK4/6i) have significantly improved clinical outcomes in patients with advanced hormone receptor-positive (HR+) breast cancer and have demonstrated favourable antitumour immune responses in preclinical studies. METHODS: Here, we investigated peripheral immune responses to ribociclib in patients with metastatic HR+ breast cancer as a preplanned exploratory subanalysis of the RIBECCA trial (NCT03096847). Peripheral blood mononuclear cells were subjected to immune cell profiling, gene expression analysis of immune-related signatures, and deep T cell receptor profiling before treatment started and after 12 weeks of treatment with ribociclib. RESULTS: Gene expression analysis revealed an upregulation of signatures associated with an activated adaptive immune system and a decrease in immunosuppressive cytokine signalling during treatment with ribociclib. Profiling of peripheral immune cell subpopulations showed a decrease in Treg cell frequencies, which was associated with treatment response. Furthermore, induction of CD4+ naive T cells could be seen, whereas effector and memory T cell populations remained largely unchanged. Correspondingly, T cell repertoire diversity remained mostly unchanged during treatment, although an increase in clonality could be observed in single patients. CONCLUSIONS: We show that treatment with ribociclib has significant effects on the peripheral innate and adaptive immune response in patients with HR+ breast cancer. Our data suggest that these effects lead to an activation of an already existing immune response rather than a de novo induction and make a strong case for future combination strategies of CDK4/6i with immunotherapies to enhance the adaptive immune response in HR+ breast cancer.
引用
- Peuker CA, Yaghobramzi S, Grunert C, et al. Treatment with ribociclib shows favourable immunomodulatory effects in patients with hormone receptor-positive breast cancer-findings from the RIBECCA trial. Eur J Cancer. 2021. PMID: 34953442. doi:10.1016/j.ejca.2021.11.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。